We studied the expression of BRCA1, ERCC1, and RRM1 which play an important role in DNA repair systems in breast cancer. Immunohistochemical staining for EGFR, BRCA1, ERCC1, and RRM1 were performed by using a tissue microarray made from 230 breast cancer patients. Patients were classified into luminal A, luminal B, HER-2, and triple negative breast cancer (TNBC) types according to ER, PR, and HER-2 expression. The expression of ERCC1, RRM1, and BRCA1 were correlated (P < 0.05). The expression level of ERCC1 was the lowest in TNBC type (P = 0.031), ERCC1 negativity was more prominent in TNBC and luminal B groups than luminal A and HER-2 groups (P = 0.013). Cases with EGFR overexpression showed high expression of RRM1 and BRCA1 (P = 0.046, an...
Mutations in BRCA1 are associated with familial as well as sporadic aggressive subtypes of breast ca...
Breast cancer in one of the most common cancer worldwide. Among women this tumor accounts for over 2...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide...
Introduction. BRCA1 dysfunction is a hallmark of both hereditary and sporadic breast cancer. BRCA1 p...
Objective: (1) The objective is to study the immunohistochemical expression of Breast cancer type 1 ...
Introduction: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombinatio...
Inherited mutations of the BRCA1 gene predispose to breast, ovarian, and other cancers. The role of ...
Purpose : The morphologic and molecular phenotype of breast cancers may help identify patients who a...
BRCA1 is a key mediator of DNA repair pathways and participates in the maintenance of the genomic in...
Background: gene expression profiling has distinguished sporadic breast tumour classes with genetic ...
Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We inve...
Breast tumours are highly heterogeneous with several distinct sub-types recognised according to thei...
International audienceAlthough it is well established that women with germ-line mutations in the BRC...
Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung can...
Mutations in BRCA1 are associated with familial as well as sporadic aggressive subtypes of breast ca...
Breast cancer in one of the most common cancer worldwide. Among women this tumor accounts for over 2...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...
The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide...
Introduction. BRCA1 dysfunction is a hallmark of both hereditary and sporadic breast cancer. BRCA1 p...
Objective: (1) The objective is to study the immunohistochemical expression of Breast cancer type 1 ...
Introduction: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombinatio...
Inherited mutations of the BRCA1 gene predispose to breast, ovarian, and other cancers. The role of ...
Purpose : The morphologic and molecular phenotype of breast cancers may help identify patients who a...
BRCA1 is a key mediator of DNA repair pathways and participates in the maintenance of the genomic in...
Background: gene expression profiling has distinguished sporadic breast tumour classes with genetic ...
Impaired DNA repair drives mutagenicity, which increases neoantigen load and immunogenicity. We inve...
Breast tumours are highly heterogeneous with several distinct sub-types recognised according to thei...
International audienceAlthough it is well established that women with germ-line mutations in the BRC...
Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung can...
Mutations in BRCA1 are associated with familial as well as sporadic aggressive subtypes of breast ca...
Breast cancer in one of the most common cancer worldwide. Among women this tumor accounts for over 2...
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10-15% are...